Is retatrutide available in Singapore? Not registered (8 Oct 2026)

Retatrutide ("reta") is not available in Singapore as a registered medicine: it is not on Singapore's register of therapeutic products (checked 8 October 2026), and HSA says no regulator has approved it as a medicine (HSA register; HSA 2026). HSA warns that "reta" sold online is not an approved medicine. GetLean does not prescribe retatrutide, but Dr Quek can assess HSA-registered options in a S$20, 30-minute video consultation. A consultation does not guarantee a prescription.

Retatrutide and orforglipron are not registered in Singapore, and GetLean does not prescribe or supply them. GetLean does prescribe and supply HSA-registered GLP-1 medications, after a consultation with Dr Quek.

Retatrutide is an investigational weekly injection from Eli Lilly. Lilly has reported six phase 3 trials since December 2025 (Lilly, December 2025; Lilly, October 2026). In TRANSCEND-T2D-2, reported on 28 October 2026, adults with type 2 diabetes lost an average of 19.5% and 20.9% on retatrutide 9 mg and 12 mg versus 9.4% on semaglutide 2 mg at 80 weeks, measured as if everyone had stayed on treatment (Lilly, October 2026). In the largest, TRIUMPH-1, average weight change at 80 weeks on the highest dose was −28.3%, measured as if everyone had stayed on treatment (Lilly, May 2026); individual results vary and are not guaranteed. Registration in Singapore would be a separate decision by the Health Sciences Authority, and no date for it has been set.

Availability in Singapore. This is an investigational medicine. It is not registered with Singapore's Health Sciences Authority, and it has no approved application with the United States Food and Drug Administration either, so it is not available through the ordinary registered-medicine route in either country. Outside clinical trials, Lilly releases it only through a pre-approval expanded access programme for a small group of adults with severe obesity who cannot join a trial, on their own doctor's request and where Lilly makes it available, and anything offered for sale under this name is not what the trials studied.

Education only. This page is general education about a medicine that is not registered in Singapore. It is not an advertisement or an offer. GetLean does not prescribe or supply retatrutide, and nothing here recommends using it.

Triple agonist: a single molecule that acts at three hormone receptors. Retatrutide acts at the receptors for GIP, GLP-1 and glucagon (Lilly, May 2026).

How does retatrutide work?

Retatrutide is one molecule that acts at three hormone receptors: GIP, GLP-1 and glucagon. In the phase 3 trials it was given once a week as an injection under the skin (Jastreboff 2026).

GLP-1 is the receptor GLP-1 medicines are named for. Semaglutide, which acts at it alone, works by mimicking a hormone the body releases after eating, and acts on areas of the brain that regulate appetite, helping people feel fuller for longer, the UK regulator says (MHRA).

GIP and glucagon are the other two. In mouse studies by Lilly's scientists, retatrutide's GIP and GLP-1 actions reduced how much the mice ate, and its glucagon action added an increase in the energy they used (Coskun 2022). In laboratory tests, it was about equally active at the glucagon and GLP-1 receptors and more active at the GIP receptor. That split between eating less and using more energy is mouse evidence; the trials in people report the overall weight change (Jastreboff 2026).

How it differs. Tirzepatide acts at two of the same receptors, GIP and GLP-1 (Jastreboff 2022), and semaglutide at one, GLP-1 (MHRA). How the trials of retatrutide, tirzepatide and semaglutide compare sets their results side by side, as the separate trials they are. Is Reta stronger than Mounjaro? sets retatrutide's trials beside Mounjaro's.

Is retatrutide "GLP-3"?

"GLP-3" is a nickname, not a medical term. Retatrutide's three targets are the GIP, GLP-1 and glucagon receptors (Jastreboff 2026), and none of them is called GLP-3.

How long does retatrutide stay in the body?

Its half-life, the time it takes for the amount in the blood to fall by half, was about 6 days in an early study of 72 adults with type 2 diabetes given weekly injections for 12 weeks. The researchers said its pharmacokinetics, how the body absorbs and clears it, suggest it suits once-weekly dosing (Urva 2022). Lilly's phase 1 single-dose study reported the same, a profile that supported once-weekly dosing (Coskun 2022), and the phase 3 trials gave it once a week (Jastreboff 2026). These figures describe the medicine Lilly tested in its studies; products sold online under the name are covered on the reta peptide page.

Where retatrutide stands in Singapore

It is not on the register. A full download of Singapore's register of therapeutic products, read on 8 October 2026, contains no product with retatrutide in its name or ingredients (HSA register). That download runs to approvals made up to 8 July 2026, so the check was repeated against HSA's own list of new drugs approved from January to August 2026, which also has none (HSA approvals). On 25 September 2026 HSA stated that no regulatory authority, including HSA, has approved retatrutide as a medicine (HSA 2026). For the legal question, see is Reta legal in Singapore?, which sets out what HSA says about sellers and about buying online.

No weight trial has run here. Two retatrutide studies list a Singapore site on ClinicalTrials.gov. Both are completed phase 1 studies in healthy volunteers, and none of the phase 2 or phase 3 weight trials lists a site in Singapore (ClinicalTrials.gov).

The special access route is narrow. Singapore does allow a hospital or clinic, with HSA's approval for each consignment, to import an unregistered medicine for a patient. HSA says such use should only be considered for life-saving therapies where there is an unmet medical need, and its named-patient category covers either a life-saving option where no effective alternative is registered, or a novel product offering a substantive clinical advantage over registered therapies. The requesting doctor is fully responsible for its use (HSA). Medicines for weight management are already registered here (Singapore NDF).

In Singapore, tirzepatide is registered as Mounjaro, and semaglutide injection as Wegovy for weight management and as Ozempic for type 2 diabetes.

What does the evidence say about retatrutide availability?

Retatrutide remains investigational: trial results and a planned filing are not medicine approvals.

Evidence or route	Date and source	Availability implication
Singapore therapeutic-product register and new-drug approvals	Checked 8 October 2026; register data to 8 July and approval listings January–August 2026	No retatrutide product found (HSA register; HSA approvals)
HSA consumer notice	25 September 2026	No regulatory authority, including HSA, has approved retatrutide as a medicine (HSA)
Lilly's announced US filing plan	July 2026 announcement: first quarter of 2027	A planned submission, not approval or a Singapore availability date (Lilly)
Lilly pre-approval expanded access	ClinicalTrials.gov entry first posted 5 June 2026	Narrow physician-requested programme; geography, supply and individual eligibility apply, not an ordinary retail prescription route (ClinicalTrials.gov)

HSA's special-access requirements are separate from Lilly's programme; neither makes a product sold online into registered medicine (HSA special access). GetLean does not prescribe or supply retatrutide.

What are "R-10" and "R-20"?

"R-10" and "R-20" are names on unapproved products sold as retatrutide. A health alert issued on 19 June 2026 by the Chief Health Officer of Victoria, Australia, listed products labelled "Retatrutide", "Reta" and "R-10, R-20" after six cases of acute liver injury in people who had used them. The alert said the toxic effects were possibly linked to a contaminant, and that the products had been bought online, through friends and through social media accounts (Victoria 2026). The alert concerns Australia, not Singapore. No regulatory authority, including HSA, has approved retatrutide as a medicine, and HSA says labels such as "research use only" or "not for human consumption" should be treated as a warning sign (HSA 2026).

What the phase 3 trials reported

The four weight-management trials below are Lilly's TRIUMPH programme. TRIUMPH-1 was published in the New England Journal of Medicine and TRIUMPH-2 in The Lancet, both on 29 September 2026 (Jastreboff 2026; Bellido 2026). The TRIUMPH-3 and TRIUMPH-4 figures come from Lilly's announcements of topline results and have not yet been published as papers. Doses were reached in steps every four weeks from 2 mg (Lilly, May 2026).

Trial (phase 3)	Who took part	Weeks	Average weight change	Placebo
TRIUMPH-1	2,339 adults with obesity or overweight and a weight-related condition, without diabetes	80	−19.0% (4 mg), −25.9% (9 mg), −28.3% (12 mg)	−2.2%
TRIUMPH-2	1,152 adults with type 2 diabetes and obesity or overweight	80	−12.7% (4 mg), −19.1% (9 mg), −20.8% (12 mg)	−4.0%
TRIUMPH-3	1,949 adults with a BMI of 35 or above and established cardiovascular disease	80	−21.6% (9 mg), −22.6% (12 mg)	−3.2%
TRIUMPH-4	445 adults with obesity or overweight and knee osteoarthritis	68	−26.4% (9 mg), −28.7% (12 mg)	−2.1%

Efficacy estimand, as reported by Lilly (TRIUMPH-1; TRIUMPH-2 and TRIUMPH-3; TRIUMPH-4). The published TRIUMPH-2 paper's primary analysis counts everyone regardless of whether they kept taking it: −11.9%, −16.8% and −18.8% against −5.1% (Bellido 2026). Individual results vary and are not guaranteed.

Two ways of counting. The table uses what Lilly calls the efficacy estimand: the result as if every participant had stayed on treatment. Counting everyone regardless of whether they kept taking it (the treatment-regimen estimand), TRIUMPH-1's figures were −17.6%, −23.7% and −25.0%, against −3.9% on placebo (Lilly, May 2026); this is the main analysis in the published paper (Jastreboff 2026). The second is the more cautious reading.

The 30% figure has a narrower base. In TRIUMPH-1, 45.3% of those on 12 mg lost 30% or more of their weight, against 0.5% on placebo, on the efficacy estimand. The −30.3% figure often quoted comes from an extension to 104 weeks that enrolled 532 participants with a BMI of 35 or above who had completed week 80 and tolerated their dose. It is the result for the group that started on 12 mg and continued at the highest dose they tolerated, on the efficacy estimand; counting everyone in that group regardless, it was −29.9% (Lilly, May 2026). It describes people who stayed on and coped with treatment, not everyone who started.

A fifth trial tested it for diabetes. TRANSCEND-T2D-1 gave retatrutide to 537 adults with type 2 diabetes for 40 weeks. Published in The Lancet in June 2026, it reported weight change of −11.5%, −13.9% and −15.3% on 4 mg, 9 mg and 12 mg against −2.6% on placebo, counting everyone (Bajaj 2026).

Where the older number came from. Before phase 3, the figure in circulation was −24.2% at 48 weeks on 12 mg, from a phase 2 trial of 338 adults (Jastreboff 2023). The TRIUMPH trials are larger and longer, which is why they replace it.

Side effects, briefly

The most common side effects in TRIUMPH-1 were digestive. Nausea was reported by 42.4% on 12 mg against 14.8% on placebo, and 11.3% on 12 mg stopped treatment because of side effects, against 4.9% on placebo (Lilly, May 2026). The side-effects page sets out each trial's figures, including dysesthesia, an unusual skin sensation that was more common on retatrutide than on placebo.

What has to happen before it could be prescribed here

1. A first approval somewhere. Lilly plans to file in the United States in the first quarter of 2027, and says it now has the data to support submissions elsewhere (Lilly, July 2026).
2. An application in Singapore. A United States approval does not register a medicine here. Lilly, or a company acting for it, would apply to HSA, and HSA would evaluate it.
3. Registration. Only once retatrutide is on Singapore's register could a doctor here prescribe it in the ordinary way.

Until then, Lilly supplies retatrutide only in its clinical trials and through a pre-approval expanded access programme, first posted on ClinicalTrials.gov on 5 June 2026, for a small group of adults with severe obesity who cannot join a trial, on their own doctor's request (ClinicalTrials.gov NCT07629401). Products sold online under the name are a different matter, covered on the reta peptide page. The overview of what is coming puts retatrutide beside the other medicines in development.

What can GetLean assess while retatrutide is investigational?

GetLean assesses whether an HSA-registered medicine is appropriate for weight management; it does not prescribe or supply retatrutide. Its registered options include Wegovy, Mounjaro and Rybelsus; Rybelsus is registered for type 2 diabetes, so weight-loss prescribing is off-label (NDF). The GLP-1 programme explains the care journey, and the pricing page gives the actual programme prices.

1. Book your consult. Tell us your health conditions, goals and any GLP-1 medication you take.
2. Meet Dr Quek by video for 30 minutes. The first consultation is S$20. He decides suitability and which medicine, if any; a consultation does not guarantee a prescription.
3. If he prescribes a medicine GetLean supplies, it is delivered to you, with daily WhatsApp coaching and Dr Quek's monthly reviews.

The programme includes a personalised nutrition and daily activity plan. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. Individual results vary. This describes medicines GetLean prescribes, not a retatrutide taper or treatment protocol. Weaning off GLP-1 explains the approach to coming off registered treatment.

For research safety information, retatrutide side effects stays specific to the trials and unapproved products. For the supplied medicines, anything clinical goes to Dr Quek through the care team on WhatsApp; an urgent symptom does not wait for a reply or the next monthly review.

Common questions

Is retatrutide available in Singapore?

No. No retatrutide product is on Singapore's register of therapeutic products (HSA register) or among the new drugs HSA approved from January to August 2026 (HSA approvals), checked 8 October 2026. HSA states that no regulatory authority, including HSA, has approved it as a medicine (HSA 2026).

When will retatrutide be available in Singapore?

No date has been set. The timetable Lilly has announced names the United States: a Biologics License Application to the FDA in the first quarter of 2027 (Lilly, July 2026). A US decision would not register the medicine here; that is a separate decision by Singapore's Health Sciences Authority.

How much weight did people lose in the phase 3 trials?

In TRIUMPH-1, average weight change at 80 weeks was −19.0%, −25.9% and −28.3% on 4 mg, 9 mg and 12 mg against −2.2% on placebo, measured as if everyone had stayed on treatment (Lilly, May 2026). Counting everyone regardless of whether they kept taking it, the figures were −17.6%, −23.7% and −25.0%. The second set is the main analysis in the trial's paper, published in the New England Journal of Medicine on 29 September 2026 (Jastreboff 2026). Individual results vary and are not guaranteed.

How much weight do people lose per week on retatrutide?

Retatrutide's phase 3 results are reported as the average loss at set points, not per week: in TRIUMPH-1, adults lost an average of 17.6%, 23.7% and 25.0% of body weight on 4 mg, 9 mg and 12 mg over 80 weeks, against 3.9% on placebo, counting everyone whether or not they kept taking it (Jastreboff 2026). Individual results vary and are not guaranteed. Retatrutide and orforglipron are not registered in Singapore, and GetLean does not prescribe or supply them. GetLean does prescribe and supply HSA-registered GLP-1 medications, after a consultation with Dr Quek.

Can a doctor in Singapore prescribe retatrutide?

Not in the ordinary way: it is not registered here. HSA's special access route lets a hospital or clinic import an unregistered medicine for a patient with HSA's approval, and HSA says such use should only be considered for life-saving therapies where there is an unmet medical need (HSA). Medicines registered for weight management already exist in Singapore (Singapore NDF).

Is "reta" the same thing as retatrutide?

"Reta" is the shorthand used by online sellers of products labelled as retatrutide. No regulator has evaluated those products, and HSA warned about them on 25 September 2026. The reta peptide page covers what HSA said.

How does retatrutide work?

It is one molecule that acts at three hormone receptors, GIP, GLP-1 and glucagon, given in the trials as a weekly injection (Jastreboff 2026). In mouse studies by Lilly's scientists, the GIP and GLP-1 actions reduced how much the mice ate and the glucagon action increased the energy they used (Coskun 2022); the human trials report the overall weight change.

How long does retatrutide stay in the body?

In an early study of 72 adults with type 2 diabetes, its half-life, the time for the amount in the blood to fall by half, was about 6 days, and the researchers said this suits once-weekly dosing (Urva 2022). The phase 3 trials gave it once a week (Jastreboff 2026).

Does retatrutide need a prescription?

It cannot be prescribed in Singapore in the ordinary way, because retatrutide is not registered here, and HSA says no regulatory authority has approved it as a medicine (HSA register; HSA 2026). Outside clinical trials, Lilly releases it only through a pre-approval expanded access programme for a small group of adults with severe obesity who cannot join a trial, on their own doctor's request (ClinicalTrials.gov NCT07629401).

What are the potential side effects of taking retatrutide?

The most common in the trials were digestive. In Lilly's topline results for TRIUMPH-1, nausea was reported by 42.4% on 12 mg against 14.8% on placebo, and 11.3% on 12 mg stopped treatment because of side effects, against 4.9% on placebo (Lilly, May 2026). The side-effects page sets out each trial's figures, including dysesthesia, an unusual skin sensation.

How much does retatrutide cost in Singapore?

GetLean has no retatrutide price and does not prescribe or supply it. Retatrutide is not registered here, and HSA states that no regulatory authority has approved it as a medicine (HSA 2026). The pricing page lists GetLean's actual programmes; prices advertised by online sellers do not establish a registered treatment route.

Is retatrutide the same as Mounjaro?

No. Retatrutide acts at GIP, GLP-1 and glucagon receptors, while tirzepatide acts at GIP and GLP-1 receptors (Jastreboff 2026; Jastreboff 2022). Mounjaro is the registered tirzepatide brand in Singapore; retatrutide vs Mounjaro compares separate trials, not a head-to-head result. Retatrutide is investigational and not supplied by GetLean.

Have retatrutide weight-loss trials run in Singapore?

The ClinicalTrials.gov search recorded for this page found two completed phase 1 studies in healthy volunteers listing Singapore sites, not phase 2 or phase 3 weight-loss trials (ClinicalTrials.gov search). A local research site does not establish medicine registration or retail availability.

Are R-10 and R-20 approved retatrutide products?

No. Victoria's Chief Health Officer named products labelled Retatrutide, Reta and R-10/R-20 in a 19 June 2026 alert after six cases of acute liver injury; a contaminant was a possible explanation (Victoria alert). That alert concerns Australia, not Singapore. HSA says no regulator has approved retatrutide as a medicine (HSA).

Does the 30.3% retatrutide result describe everyone who started?

No. It came from a 104-week extension enrolling 532 participants with a BMI of at least 35 who completed week 80 and tolerated their dose, rather than everyone who began TRIUMPH-1 (Lilly, May 2026). The figure was the efficacy-estimand result for those starting on 12 mg and continuing at their highest tolerated dose. Individual results vary and are not guaranteed.

Have all the retatrutide phase 3 results been published as papers?

The sources recorded here include published TRIUMPH-1 and TRIUMPH-2 papers dated 29 September 2026 (Jastreboff; Bellido). This page's TRIUMPH-3 and TRIUMPH-4 figures come from Lilly's topline announcements rather than published papers (Lilly July 2026; Lilly December 2025). Trial publication and medicine approval are different steps.

Can GetLean assess registered options while I wait for retatrutide?

Yes. Dr Quek can assess whether a registered medicine GetLean supplies suits you at a S$20, 30-minute video consultation; a prescription is not guaranteed. GetLean does not prescribe or supply retatrutide. If medication is prescribed, the programme includes delivery, daily WhatsApp coaching, monthly reviews and the GetLean GLP-1 Taper Plan towards the lowest effective dose and, where clinically appropriate, off the medication.